Overview
PolyPid reports Q3 net loss of $7.5 mln, down from $7.8 mln last year
Company advances regulatory strategy with pre-NDA meeting scheduled for December
PolyPid progresses in U.S. partnership talks post positive Phase 3 trial results
Outlook
PolyPid plans NDA submission for D-PLEX₁₀₀ in early 2026
Company advancing U.S. partnership discussions for D-PLEX₁₀₀
PolyPid expects cash balance to fund operations into 2026
Result Drivers
R&D - The increase in R&D expenses was primarily due to activities related to the completion of the SHIELD II Phase 3 trial and preparation for regulatory submissions
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 EPS | $0.37 | ||
Q3 Net Income | $7.45 mln | ||
Q3 Operating Income | $7.46 mln | ||
Q3 Pretax Profit | $7.43 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for PolyPid Ltd is $13.00, about 71.1% above its November 11 closing price of $3.76
Press Release: ID:nGNX9rSTFN
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)